There is a lack of consensus regarding the causes of the differences in the higher incidence of and the mortality from head and neck squamous cell carcinoma (HNSCC) in African Americans (AA) versus Caucasian Americans (CA). We examined a comprehensive array of risk factors influencing health and disease in an access-to-care, racially diverse, primary HNSCC cohort.
Study Design
Cross-sectional study.
Setting
Primary care academic health care system.
Subjects and Methods
The cohort of 673 patients comprised 391 CA and 282 AA (42%). Risk variables included demographic, histopathology, and clinical/epidemiologic factors. Tumor DNA was interrogated for loss and gain of 113 genes with known involvement in HNSCC/cancer. Logistic regression for univariate analysis was followed by multivariate modeling with determination of model predictability (c-index).
Results
Of the 39 univariate differences between AA and CA, multivariate modeling (c-index = 0.81) retained 7 differences (P < .05). AA were less likely to be married and more likely to have tumor lymphocytic response, undergo radiation treatment, and smoke. Insurance type was a significant predictor of race. AA were more likely to have Medicaid, Medicare, and other HMO types. AA tumors were more likely to have loss of CDKN2A and gain of SCYA3 versus CA.
Conclusions
Multivariate modeling indicated significant differences between AA and CA HNSCC for histopathology, treatment, smoking, marital status, type of insurance, and tumor gene copy number alterations. Our data reiterate that for HNSCC, as in the case of other complex diseases, tumor genetics or biology is only one of many potential contributors to differences among racial groups.
HoffmanHTKarnellLHFunkGF. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124:951-962.
3.
ShaversVLHarlanLCWinnD. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev. 2003;22:25-38.
4.
ArbesSJJrOlshanAFCaplanDJ. Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States). Cancer Causes Control. 1999;10:513-523.
5.
GoodwinWJThomasGRParkerDF. Unequal burden of head and neck cancer in the United States. Head Neck. 2008;30:358-371.
6.
GourinCGPodolskyRH. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 2006;116:1093-1106.
7.
MurdockJMGluckmanJL. African-American and white head and neck carcinoma patients in a university medical center setting. Are treatments provided and are outcomes similar or disparate?Cancer. 2001;91:279-283.
8.
SettleKPosnerMRSchumakerLM. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila Pa). 2009;2:776-781.
9.
HashibeMBrennanPBenhamouS. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99:777-789.
10.
GillisonMLLowyDR. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004;363:1488-1489.
11.
AngKKHarrisJWheelerR. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
12.
WienckeJK. Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer. 2004;4:79-84.
13.
PiccirilloJFCostasIClaybourP. The measurement of comorbidity by cancer registries. J Reg Manage. 2003;30:8-14.
14.
NaqviKGarcia-ManeroGSardesaiS. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29:2240-2246.
15.
ChenKSawhneyRKhanM. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1131-1138.
16.
WorshamMJPalsGSchoutenJP. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:702-708.
17.
WorshamMJChenKMTiwariN. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:409-415.
18.
WorshamMJPalsGSchoutenJP. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat. 2006;96:177-186.
19.
KunjoonjuJPRaitanenMGrenmanS. Identification of individual genes altered in squamous cell carcinoma of the vulva. Genes Chromosomes Cancer. 2005;44:185-193.
20.
SiegelRWEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
WardEHalpernMSchragN. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:9-31.
23.
BachPBSchragDBrawleyOW. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113.
24.
LongSAD’AntonioLLRobinsonEB. Factors related to quality of life and functional status in 50 patients with head and neck cancer. Laryngoscope. 1996;106:1084-1088.
25.
Annual smoking—attributable mortality, years of potential life lost, and economic costs—United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;51:300-303.
26.
Brandwein-GenslerMTeixeiraMSLewisCM. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167-178.
27.
HiratsukaHMiyakawaANakamoriK. Multivariate analysis of occult lymph node metastasis as a prognostic indicator for patients with squamous cell carcinoma of the oral cavity. Cancer. 1997;80:351-356.
28.
KurokawaHYamashitaYMurataT. Histological grading of malignancy correlates with regional lymph node metastasis and survival of patients with oral squamous cell carcinoma. Fukuoka Igaku Zasshi. 1998;89:225-231.
29.
SilvaTARibeiroFLOliveira-NetoHH. Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense. Oncol Rep. 2007;18:1107-1113.
FolkmanJ. Angiogenesis. Annu Rev Med. 2006;57:1-18.
32.
HaberDA. Splicing into senescence: the curious case of p16 and p19ARF. Cell. 1997;91:555-558.
33.
XingEPNieYSongY. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5:2704-2713.
34.
LydiattWMDavidsonBJSchantzSP. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck. 1998;20:113-118.
35.
ReedALCalifanoJCairnsP. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996;56:3630-3633.
36.
YarbroughWG. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope. 2002;112:2114-2128.
37.
NamazieAAlaviSOlopadeOI. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002;112:472-481.
38.
PsyrriADiMaioD. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008;5:24-31.
39.
ProostPWuytsAvan DammeJ. The role of chemokines in inflammation. Int J Clin Lab Res. 1996;26:211-223.
40.
YangXLuPFujiiC. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer. 2006;118:1869-1876.
